Amalgamated Bank’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Amalgamated Bank’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,075	Closed	-$6K	–	1442
2016 Q1	$6K	Buy	+1,075	New	+$14K	﹤0.01%	1297
2015 Q4	–	Sell	-1,069	Closed	-$23K	–	1327
2015 Q3	$23K	Buy	1,069 +10	+0.9%	+$343	﹤0.01%	1290
2015 Q2	$52K	Sell	1,059 -177	-14%	-$10.6K	0.01%	1331
2015 Q1	$97K	Buy	1,236 +47	+4%	+$2.92K	0.01%	907
2014 Q4	$72K	Buy	1,189 +54	+5%	+$2.71K	0.01%	836
2014 Q3	$48K	Hold	1,135	–	–	0.01%	825
2014 Q2	$70K	Sell	1,135 -11	-1%	-$640	0.01%	853
2014 Q1	$75K	Buy	1,146 +94	+9%	+$6.36K	0.01%	806
2013 Q4	$59K	Buy	+1,052	New	+$59.1K	0.01%	817

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Amalgamated Bank's OREX Position: Q2 2016 in Review

Amalgamated Bank sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 1,075 shares — an estimated $6K sold.

Amalgamated Bank first reported a position in OREX in Q4 2013 and held it in 9 quarters. The position peaked at $97K in Q1 2015. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

Amalgamated Bank reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
Amalgamated Bank sold 1,075 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $6K.
Amalgamated Bank first reported a position in Orexigen Therapeutics, Inc. in Q4 2013 and held it in 9 quarters.
Amalgamated Bank's Orexigen Therapeutics, Inc. position peaked at $97K in Q1 2015.
73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Amalgamated Bank's 13F filing for Q2 2016, filed 16 Aug 2016.